Pacira BioSciences, Inc.PCRXEarnings & Financial Report
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PCRX Q1 FY2026 Key Financial Metrics
Revenue
$177.4M
Gross Profit
N/A
Operating Profit
$6.9M
Net Profit
$2.9M
Gross Margin
N/A
Operating Margin
3.9%
Net Margin
1.6%
YoY Growth
5.0%
EPS
$0.07
Pacira BioSciences, Inc. Q1 FY2026 Financial Summary
Pacira BioSciences, Inc. reported revenue of $177.4M (up 5.0% YoY) for Q1 FY2026, with a net profit of $2.9M (1.6% margin).
Key Financial Metrics
| Total Revenue | $177.4M |
|---|---|
| Net Profit | $2.9M |
| Gross Margin | N/A |
| Operating Margin | 3.9% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Pacira BioSciences, Inc. Q1 FY2026 revenue of $177.4M breaks down across 4 segments, led by EXPAREL at $143.3M (80.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| EXPAREL | $143.3M | 80.8% |
| ZILRETTA | $26.8M | 15.1% |
| iovera° | $6.2M | 3.5% |
| Bupivacaine liposome injectable suspension | $1.2M | 0.7% |
Pacira BioSciences, Inc. Revenue by Segment — Quarterly Trend
Pacira BioSciences, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as EXPAREL and ZILRETTA) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| EXPAREL | $143.3M | $155.8M | $139.9M | $142.9M |
| ZILRETTA | $26.8M | $33.0M | $29.0M | $31.3M |
| iovera° | $6.2M | — | — | — |
| Bupivacaine liposome injectable suspension | $1.2M | — | — | — |
Pacira BioSciences, Inc. Annual Revenue by Year
Pacira BioSciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $726.4M).
Pacira BioSciences, Inc. Quarterly Revenue & Net Profit History
Pacira BioSciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $177.4M | +5.0% | $2.9M | 1.6% |
| Q4 FY2025 | $196.9M | +5.1% | N/A | N/A |
| Q3 FY2025 | $179.5M | +6.5% | $5.4M | 3.0% |
| Q2 FY2025 | $181.1M | +1.7% | $-4.8M | -2.7% |
| Q1 FY2025 | $168.9M | +1.1% | $4.8M | 2.8% |
| Q4 FY2024 | $187.3M | +3.3% | N/A | N/A |
| Q3 FY2024 | $168.6M | +2.8% | $-143.5M | -85.1% |
| Q2 FY2024 | $178.0M | +5.0% | $18.9M | 10.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $178.0M | $168.6M | $187.3M | $168.9M | $181.1M | $179.5M | $196.9M | $177.4M |
| YoY Growth | 5.0% | 2.8% | 3.3% | 1.1% | 1.7% | 6.5% | 5.1% | 5.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.65B | $1.52B | $1.55B | $1.59B | $1.54B | $1.30B | $1.26B | $1.21B |
| Liabilities | $767.5M | $772.1M | $775.2M | $788.1M | $779.5M | $570.4M | $571.8M | $554.6M |
| Equity | $879.3M | $749.6M | $778.3M | $798.5M | $757.8M | $727.2M | $693.1M | $653.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $53.2M | $53.9M | $33.1M | $35.5M | $12.0M | $60.8M | $43.7M |